证券日报网2月4日讯 ，西山科技在接受调研者提问时表示，《手术与治疗辅助操作类医疗服务价格项 目立项指南（试行）》聚焦医疗技术前沿成果，围绕3D打印、示踪增强成像、能量器械、术中影像引 导、机械臂与远程手术等医疗科技创新成果进行统一价格立项，规范形成37项价格项目。这与公司"微 创手术工具整体方案提供者"的战略定位高度契合，公司产品线涵盖手术动力装置、内窥镜系统、能量 手术设备等，正是该指南中第12项、第15项、第20项、第23项重点支持的技术领域。具体来看，指南对 手术动力装置及能量手术器械（如超声刀、射频刀、等离子刀等）的收费政策进行了规范，有助于规范 相关耗材的使用及收费行为，为公司手术动力装置及能量手术设备相关耗材的使用创造更加积极的市场 环境。公司将继续深化耗材化战略，着力推动手术动力装置的持续普及应用及其刀头的耗材化。 （文章来源：证券日报） ...

证券日报网2月4日讯 ，西山科技在接受调研者提问时表示，在国际市场拓展方面，公司持续加大国际 注册与推广投入，产品已覆盖全球46个国家和地区。2025年下半年，公司手术动力装置产品成功获得欧 盟CE-MDR认证，这一重要资质将对未来国际产品准入及销售产生显著的积极影响。公司也将依托手术 动力装置取得CE认证的经验，加速推进内窥镜、等离子等多产品的注册，以及手术动力装置、能量手 术设备与内窥镜相关产品在全球的注册及准入。此外，公司通过筛选目标国家具备公司现有优势科室的 区域资源与渠道的经销商建立合作，授权其负责当地市场的推广、渠道建设及终端医院的销售拓展，同 时公司会为经销商提供必要的产品培训与业务指导，以保障国际业务的稳健增长。综上所述，公司通过 夯实产品技术基础、获取关键国际认证、构建全球经销网络以及清晰的战略路径，为国际市场的长远发 展奠定了坚实基础。公司致力于寻找专业、优质、合适的国际合作伙伴，通过强强联合提升市场拓展的 宽度和效率，海外市场的发展前景值得期待。 （文章来源：证券日报） ...

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

Core Viewpoint - The arbitration cases involving Chongqing Xishan Technology Co., Ltd. have been withdrawn, and this decision will not significantly impact the company's daily operations or profits [1][6]. Group 1: Arbitration Case Overview - The company was involved in arbitration initiated by China National Pharmaceutical Group United Medical Devices Co., Ltd. and China National Pharmaceutical Group Beijing United Meidi Medical Devices Co., Ltd. [2] - The arbitration claims amounted to approximately 35.71 million yuan, but the specific compensation obligations and amounts remain unclear [1][2]. Group 2: Arbitration Progress - The Beijing Arbitration Commission accepted the arbitration case on August 29, 2025, under the case number (2025) Jingzhong Anzi No. 07963 [3]. - The arbitration tribunal decided to withdraw the case on January 9, 2026, following the applicant's request to withdraw all arbitration claims [4]. Group 3: Financial Implications - The arbitration fees for the first case totaled 107,956.39 yuan, with the remaining fees refunded to the applicant [4]. - The arbitration fees for the second case amounted to 83,575.2 yuan, with the remaining fees also refunded [6].

证券代码：688576 证券简称：西山科技 公告编号：2026-002 重庆西山科技股份有限公司 关于收到北京仲裁委员会撤案决定 暨公司涉及仲裁事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 具体内容如下： "北京仲裁委员会（以下称本会）根据申请人国药集团联合医疗器械有限公 司（以下称申请人）向本会提交的以被申请人北京德聚和医疗技术有限公司（以 下称被申请人一）、被申请人重庆西山科技股份有限公司（以下称被申请人二， 同被申请人一以下合称被申请人）为被申请人的仲裁申请书，以及签订的四份《医 疗器械产品配送业务合作协议》（以下称本案合同）中的仲裁条款及有关法律的 规定，于 2025 年 8 月 29 日受理了申请人与被申请人之间因本案合同所引起的争 议仲裁案（以下称本案）。本案编号为（2025）京仲案字第 07963 号。 案件所处的仲裁阶段：申请人撤销仲裁。 上市公司所处的当事人地位：重庆西山科技股份有限公司（以下简称"公 司"）为被申请人之一，承担连带赔偿责任。 涉案金额：根据对方提交的仲裁 ...

Core Viewpoint - The announcement details the completion of the share buyback plan by the controlling shareholder of Chongqing Xishan Technology Co., Ltd., confirming the execution of the plan and the amount of shares acquired [2][3]. Group 1: Buyback Plan Disclosure - The company disclosed a share buyback plan on July 8, 2025, intending to use its own or raised funds to purchase shares worth between RMB 5 million and RMB 10 million within six months [2]. - The controlling shareholder, Xishan Investment, aimed to enhance confidence in the company's future development and long-term investment value [2]. Group 2: Implementation Results - From July 10, 2025, to January 7, 2026, Xishan Investment acquired a total of 77,335 A-shares, representing approximately 0.17% of the company's total share capital, with a total expenditure of RMB 501.17 million (excluding transaction fees) [2][3]. - The buyback plan's lower limit was met, and the plan was completed within the specified timeframe [3]. Group 3: Legal Compliance - The law firm Jiangsu Century Tongren confirmed that the buyback was conducted in compliance with relevant laws and regulations, including the Acquisition Management Measures and Regulatory Guidelines [4]. - The buyback did not trigger a mandatory tender offer and will not affect the company's governance structure or ongoing operations [5]. Group 4: Commitment and Disclosure - Xishan Investment committed not to reduce its holdings of the company's shares within the legal timeframe [6]. - The company fulfilled its information disclosure obligations in accordance with applicable laws and regulations [6].

Group 1 - Xishan Technology announced on January 7 that it has completed its share buyback plan, acquiring approximately 77,300 A-shares, which represents about 0.17% of the company's total share capital as of the announcement date [1] - The total amount spent on the share buyback was 5.0117 million RMB, exceeding the lower limit of the planned buyback range [1] - The buyback period was from July 10, 2025, to January 7, 2026, indicating a strategic move to enhance shareholder value [1] Group 2 - The Shanghai Composite Index has recently stabilized at a key position for the first time in ten years, suggesting a positive market sentiment [1] - Goldman Sachs has recommended an overweight position in Chinese stocks, reflecting confidence in the market's recovery [1] - Analysts from brokerage firms noted that factors such as the appreciation of the RMB are accelerating the return of cross-border capital [1]

证券代码：688576 证券简称：西山科技 公告编号：2026-001 重庆西山科技股份有限公司 关于控股股东增持公司股份计划 实施完毕暨结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 7 月 8 日在上 海证券交易所网站（www.sse.com.cn）披露了《重庆西山科技股份有限公司关于 控股股东增持股份计划的公告》（公告编号：2025-031）。基于对公司未来发展的 信心和长期投资价值认可，公司控股股东重庆西山投资有限公司（以下简称"西 山投资"）拟自 2025 年 7 月 8 日起 6 个月内，使用其自有资金或自筹资金，通 过上海证券交易所系统允许的方式（包括但不限于集中竞价、大宗交易等）增持 公司股份，增持金额不低于人民币 500 万元（含），不超过人民币 1,000 万元（含） （以下简称"本次增持计划"）。 增持计划的实施结果 自 2025 年 7 月 10 日首次增持起至 2026 年 1 月 7 ...

RINERS 载师事务所 关于重庆西山科技股份有限公司 控股股东增持股份专项核查的法律意见书 苏同律证字 2026 第[008]号 南京市建邺区贤坤路江岛智立方 Ｃ座 ４层 邮编:210019 电 话 :+86 25-83304480 传 真 :+86 25-83329335 江苏世纪同仁律师事务所 关于重庆西山科技股份有限公司 控股股东增持股份专项核查的法律意见书 - 1 - the state of the state 苏同律证字 2026 第[008]号 致:重庆两山科技股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》(以下简称"《证券法》")、《上市公司收购管理办法》(2025 修正)(以下简称"《收购管理办法》")及《上海证券交易所上市公司自律监 管指引第 8 号 -- 股份变动管理(2025年4月修订)》(以下简称"《监管指 引第 8号》")等法律、法规、规章及规范性文件的有关规定,本所接受重庆西 山科技股份有限公司(以下简称"西山科技")委托,就西山科技控股股东重庆 两山投资有限公司(以下简称"西山投资"或"增持人")于2025年7月8日 至 20 ...

Core Viewpoint - Xishan Technology announced that its controlling shareholder, Xishan Investment, planned to increase its stake in the company by no less than 5 million yuan and no more than 10 million yuan within six months starting from July 8, 2025 [1] Group 1 - From July 10, 2025, to January 7, 2026, Xishan Investment cumulatively increased its holdings by 77,335 shares, accounting for 0.17% of the total share capital, with an investment amount of 5.0117 million yuan, reaching the lower limit of the planned increase [1] - After the completion of the share increase, Xishan Investment and its concerted parties raised their shareholding ratio to 52.37% and committed not to reduce their holdings within the statutory period [1]